Search Medical Condition
Please enter condition
Please choose location from dropdown

Nordhorn, Germany Clinical Trials

A listing of Nordhorn, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

The main purpose of this study is evaluation of deep molecular response (MR4.5; BCR-ABL IS < 0.0032%) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase CML. Via the use of MR4.5 EUTOS ('European Treatment and Outcome Study for CML') laboratories adequate and reliable molecular ...

Phase

1.0 miles

Learn More »

Patient Preference for Pegfilgrastim (Neulasta ) Application Forms

Neutropenia is one of the most common side effects of myelosuppressive chemotherapy. Febrile neutropenia and infectious complications are associated with chemotherapy dose delays and reductions and an increased risk of hospitalization. Prophylaxis with recombinant G-CSFs reduces the incidence, severity and duration of CIN and the risk of developing FN. Pegfilgrastim ...

Phase N/A

1.0 miles

Learn More »

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery

Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of ...

Phase N/A

1.0 miles

Learn More »

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto Respimat (AERIAL )

The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto Respimat according to label after approximately 6 weeks in routine clinical practice. In visit 1, patient data on demographics, smoking status, medical history, breathlessness, general ...

Phase N/A

9.23 miles

Learn More »

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to <18 years will be enrolled, of which at least 30 will be ...

Phase

9.23 miles

Learn More »

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Study of the long term safety of serlopitant for the treatment of pruritus in adults.

Phase

9.23 miles

Learn More »

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Phase

9.23 miles

Learn More »

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Phase

9.23 miles

Learn More »

Study of the Efficacy Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Phase

9.23 miles

Learn More »

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments

Phase

9.23 miles

Learn More »